Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Optimi Health Corp. has announced the production of two microdose psilocybin finished drug products, formulated at 1 mg and 2 mg dosages. These products are intended for use by qualified, authorized clinical research organizations. The company emphasizes that these microdose formats provide consistent, validated doses, addressing a key need in controlled research, unlike the variable psilocybin content found in natural mushrooms. These new offerings extend Optimi’s existing psilocybin product line, which includes a 5 mg formulation already prescribed for treatment-resistant depression in Australia. The entire production process, from cultivation to encapsulation, is conducted in-house at Optimi’s GMP facility in Princeton, British Columbia, under its Health Canada Drug Establishment License. Optimi supplies both psilocybin and MDMA drug products to regulated markets globally for clinical trials and patient access programs.